Shelton Capital Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$20.1M Sell
143,875
-4,344
-3% -$608K 0.44% 53
2025
Q4
$18.2M Buy
148,219
+4,055
+3% +$493K 0.36% 69
2025
Q3
$16M Sell
144,164
-3,290
-2% -$374K 0.34% 67
2025
Q2
$16.3M Sell
147,454
-3,380
-2% -$360K 0.38% 60
2025
Q1
$16.9M Sell
150,834
-4,748
-3% -$490K 0.4% 60
2024
Q4
$14.4M Sell
155,582
-3,867
-2% -$348K 0.36% 61
2024
Q3
$13.4M Buy
159,449
+380
+0.2% +$29K 0.34% 67
2024
Q2
$10.9M Buy
159,069
+183
+0.1% +$12.2K 0.3% 76
2024
Q1
$11.6M Sell
158,886
-50,955
-24% -$3.92M 0.33% 74
2023
Q4
$17M Sell
209,841
-101,172
-33% -$7.87M 0.54% 35
2023
Q3
$23.3M Buy
311,013
+45,787
+17% +$3.52M 0.85% 18
2023
Q2
$20.4M Buy
265,226
+59,389
+29% +$4.74M 0.73% 18
2023
Q1
$17.1M Buy
205,837
+183,237
+811% +$15.2M 0.71% 22
2022
Q4
$1.94M Sell
22,600
-102,683
-82% -$8.13M 0.2% 166
2022
Q3
$7.73M Sell
125,283
-116,775
-48% -$7.36M 0.37% 75
2022
Q2
$15M Sell
242,058
-5,396
-2% -$334K 0.67% 26
2022
Q1
$14.7M Buy
247,454
+10,884
+5% +$696K 0.54% 35
2021
Q4
$17.2M Buy
236,570
+52,511
+29% +$3.62M 0.61% 28
2021
Q3
$12.9M Sell
184,059
-4,159
-2% -$292K 0.5% 40
2021
Q2
$13M Sell
188,218
-206,814
-52% -$13.8M 0.49% 41
2021
Q1
$25.5M Buy
395,032
+166,793
+73% +$10.8M 0.89% 20
2020
Q4
$13.3M Buy
228,239
+33,425
+17% +$2.02M 0.6% 32
2020
Q3
$12.3M Buy
194,814
+18,494
+10% +$1.28M 0.51% 35
2020
Q2
$13.6M Buy
176,320
+33,260
+23% +$2.55M 0.75% 28
2020
Q1
$10.7M Sell
143,060
-72,910
-34% -$5.04M 0.78% 26
2019
Q4
$14M Buy
215,970
+64,812
+43% +$4.22M 0.78% 24
2019
Q3
$9.58M Sell
151,158
-12,761
-8% -$834K 0.57% 37
2019
Q2
$11.1M Buy
163,919
+153,263
+1,438% +$10.1M 0.64% 30
2019
Q1
$164K Sell
10,656
-153,228
-93% -$10.2M 0.65% 23
2018
Q4
$10.3M Hold
163,884
0.7% 28
2018
Q3
$12.7M Sell
163,884
-20,600
-11% -$1.56M 0.72% 26
2018
Q2
$13.1M Buy
184,484
+4,309
+2% +$304K 0.81% 21
2018
Q1
$13.6M Buy
180,175
+6,125
+4% +$487K 0.89% 18
2017
Q4
$12.5M Sell
174,050
-5,361
-3% -$407K 0.8% 21
2017
Q3
$14.5M Sell
179,411
-23,600
-12% -$1.8M 0.98% 15
2017
Q2
$14.4M Buy
203,011
+46,887
+30% +$3.12M 1.02% 15
2017
Q1
$10.6M Buy
156,124
+18,155
+13% +$1.28M 0.73% 19
2016
Q4
$9.88M Sell
137,969
-8,700
-6% -$647K 0.75% 20
2016
Q3
$11.6M Buy
146,669
+8,013
+6% +$651K 0.97% 19
2016
Q2
$11.6M Sell
138,656
-3,962
-3% -$352K 1.02% 14
2016
Q1
$13.1M Buy
142,618
+400
+0.3% +$36.1K 1.19% 11
2015
Q4
$14.4M Buy
142,218
+6,370
+5% +$663K 1.39% 9
2015
Q3
$13.3M Buy
135,848
+7,395
+6% +$821K 1.47% 8
2015
Q2
$15M Buy
128,453
+6,884
+6% +$752K 1.56% 6
2015
Q1
$11.9M Buy
121,569
+12,834
+12% +$1.3M 1.29% 7
2014
Q4
$10.2M Buy
108,735
+16,562
+18% +$1.71M 1.19% 11
2014
Q3
$9.81M Buy
92,173
+6,086
+7% +$596K 1.32% 8
2014
Q2
$7.14M Buy
86,087
+2,594
+3% +$202K 1% 11
2014
Q1
$5.92M Buy
83,493
+4,304
+5% +$338K 0.87% 15
2013
Q4
$5.95M Buy
79,189
+1,334
+2% +$92.9K 0.9% 14
2013
Q3
$4.89M Sell
77,855
-4,639
-6% -$277K 0.82% 18
2013
Q2
$4.22M Buy
+82,494
New +$4.3M 0.77% 23

Other funds holding GILD

Shelton Capital Management's GILD Position: Q1 2026 in Review

Shelton Capital Management reduced its Gilead Sciences (GILD) stake by 2.9% in Q1 2026, selling an estimated $608K and leaving 143,875 shares worth $20.1M. The position accounts for 0.44% of the portfolio, ranked #53.

Shelton Capital Management first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $25.5M in Q1 2021. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Shelton Capital Management held 143,875 shares of Gilead Sciences worth $20.1M as of Q1 2026.
  • Shelton Capital Management sold 4,344 Gilead Sciences shares in Q1 2026, an estimated $608K.
  • Gilead Sciences made up 0.44% of Shelton Capital Management's portfolio in Q1 2026, its #53 holding.
  • Shelton Capital Management first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • Shelton Capital Management's Gilead Sciences position peaked at $25.5M in Q1 2021.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Shelton Capital Management's 13F filing for Q1 2026, filed 15 May 2026.